Johnson & Johnson Tecvayli — Percent Change (as a percent) decreased by 61.7% to 40.6% in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 54.0%, from 88.3% to 40.6%. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive percentage indicates accelerating sales momentum and market penetration, whereas a negative percentage suggests a deceleration in growth or potential market saturation.
This metric measures the period-over-period percentage growth or decline in net sales for the Tecvayli product line. It...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for specific high-growth pharmaceutical products across the industry.
jnj_segment_tecvayli_percent_change_as_a_percent| Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|
| Value | 70.4% | 88.3% | 57% | 106.1% | 40.6% |
| QoQ Change | — | +25.4% | -35.4% | +86.1% | -61.7% |
| YoY Change | — | — | — | +50.7% | -54.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.